Hirudin injection - SimcereAlternative Names: rh-RGD-Hirudin
Latest Information Update: 24 Jul 2015
At a glance
- Originator Simcere Pharmaceutical Group
- Class Antithrombins; Hirudins
- Mechanism of Action Thrombin inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 06 Jul 2011 Phase-II clinical trials in Thrombosis in China (Parenteral)